Qube Research & Technologies (QRT)
PRLD icon

Qube Research & Technologies (QRT)’s Prelude Therapeutics PRLD Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.9K Sell
13,110
-3,307
-20% -$14.4K ﹤0.01% 3076
2026
Q1 		$56.1K Sell
16,417
-5,134
-24% -$13.5K ﹤0.01% 3153
2025
Q4 		$62.5K Buy
+21,551
New +$36.4K ﹤0.01% 3258
2024
Q3 		– Sell
-3,126
Closed -$11.9K – 3935
2024
Q2 		$11.9K Buy
+3,126
New +$12.7K ﹤0.01% 2947
2023
Q2 		– Sell
-30,377
Closed -$173K – 2871
2023
Q1 		$173K Buy
30,377
+17,250
+131% +$105K ﹤0.01% 1984
2022
Q4 		$79.3K Buy
+13,127
New +$84.1K ﹤0.01% 2053
2022
Q1 		– Sell
-23,384
Closed -$291K – 2875
2021
Q4 		$291K Buy
+23,384
New +$380K ﹤0.01% 1819

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Qube Research & Technologies (QRT)'s PRLD Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its Prelude Therapeutics (PRLD) stake by 20% in Q2 2026, selling an estimated $14.4K and leaving 13,110 shares worth $69.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3076.

Qube Research & Technologies (QRT) first reported a position in PRLD in Q4 2021 and has held it in 7 quarters since. The position peaked at $291K in Q4 2021. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Qube Research & Technologies (QRT) held 13,110 shares of Prelude Therapeutics worth $69.9K as of Q2 2026.
  • Qube Research & Technologies (QRT) sold 3,307 Prelude Therapeutics shares in Q2 2026, an estimated $14.4K.
  • Prelude Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #3076 holding.
  • Qube Research & Technologies (QRT) first reported a position in Prelude Therapeutics in Q4 2021 and has held it in 7 quarters since.
  • Qube Research & Technologies (QRT)'s Prelude Therapeutics position peaked at $291K in Q4 2021.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.